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Background: Over the last decade, significant progresses have been achieved in the development and validation
of new tools for the evaluation of disease activity in axial spondyloarthritis (SpA). Despite they play a key role in the
assessment of these patients, the calculation scores are relatively complex and difficult to be quickly assessed in the
busy daily clinical practice.
Objectives: To test the construct validity of the Simplified Ankylosing Spondylitis Disease Activity Score (SADSAS)
to define disease activity and compare its internal and external responsiveness with the Ankylosing Spondylitis
Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with
axial SpA.
Methods: The patient cohort comprised 397 consecutive axial SpA patients who had never been treated with
tumor necrosis factor (TNF) blockers. Clinical and laboratory outcome assessments were performed at baseline, and
at week 24. The following parameters were evaluated: BASDAI, ASDAS-CRP, ASDAS-ESR, and SASDAS. Construct
convergent validity was evaluated by correlating SASDAS with ASDAS CRP/ESR, BASDAI, Bath Ankylosing Spondylitis
Functional Index (BASFI) and EuroQol five-dimensional (EQ-5D) questionnaire. One hundred and fifty-six patients
were observed longitudinally for 6 months. Responsiveness was assessed after six months of treatment with
sulfasalazine (SSZ) or biologics. Internal responsiveness was evaluated by using the effect size (ES) and standardized
response mean (SRM). External responsiveness was investigated by receiver operating characteristic (ROC) analysis.
Change scores were compared by calculating paired t-test statistic for the difference.
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Results: In testing for convergent validity a strong correlations (p < 0.0001) were observed between both SASDAS
and ASDAS-ESR (r = 0.835), and ASDAS-CRP (r = 0.805). Strong correlations (p < 0.0001) were also found between
SASDAS and BASDAI score (r = −0.886), SASDAS and BASFI scores (rho = 0.588) and SASDAS and EQ-5D scores
(rho = −0.579). The cross-classification showed a significant overall agreement (defined as the percentage of
observed exact agreements) for SASDAS vs ASDAS-ESR (weighted k = 0.704) and for SASDAS vs ASDAS-CRP
(k = 0.661). The most efficient composite measure in detecting change was the ASDAS-CRP (ES 1.95 and SRM 0.97).
The responsiveness of SASDAS was slightly higher to ASDAS-ESR with an ES of 1.62 and 1.33, and an SRM of 0.88
and 0.71, respectively. The BASDAI appear to be the less responsive (ES = 0.93 and SRM = 0.52). The area under
ROC curve of the SASDAS gives similar results to those provided by ASDAS CRP/ESR. The score changes of all
combinations were highly correlated (p < 0.0001).
Conclusions: The new SASDAS is a highly effective measure in assessing disease activity and it showed comparable
internal and external responsiveness with respect to the ASDAS ESR/CRP response criteria in patients with axial SpA.
SASDAS is easy to calculate and, therefore, appear suitable for clinical decision making, epidemiologic research, and
clinical trials.
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Axial spondyloarthritis (SpA) include diseases with pre-
dominantly axial involvement, such as ankylosing spon-
dylitis (AS), psoriatic arthritis (PsA) and non-radiographic
axial SpA which have as key symptoms both inflammatory
back pain and stiffness [1-4].
Over the last decade, significant advances have been
achieved in the development and validation of new tools
for the evaluation of disease activity in axial SpA [5].
Most of them are based on self-reported questionnaires
that include evaluation of pain and stiffness, patient’s or
physician’s global assessment (PtGA or PhGA, respect-
ively), acute phase reactants evaluation or on the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI)
[6] which is most frequently used in clinical trials. Al-
though BASDAI has been endorsed by ASAS for the treat-
ment monitoring and measurement of disease activity in
axial SpA [7], it demonstrated to have a limited face and
construct validity. Moreover it is not sensitive to change
(lack of responsivity) [8] and does not include any object-
ive measures of activity [9]. Recently, AS Disease Activity
Score (ASDAS) has been proposed by ASAS working
Group for the evaluation of disease activity in patients
with AS [10,11]. ASDAS is the first validated disease
activity system which combines both patient-reported out-
come measures and acute-phase reactants levels. However,
the equation used to calculate the ASDAS score is rela-
tively complex (since requires a calculator) to be quickly
assessed in the busy daily clinical practice. In this way
Sommerfleck et al. [12] developed a simplified version of
the ASDAS, named Simplified AS Disease Activity Score
(SASDAS) which, keeping the sensitive characteristics of
the ASDAS, can be considered an intuitive and easy way
to assess the disease activity in patients with axial SpA.
SASDAS is based on the recently developed diseaseactivity indices for rheumatoid arthritis (RA) such as the
Simplified Disease Activity Index (SDAI) [13] and disease
activity index for the assessment of reactive arthritis
(DAREA) [14] which demonstrated to be valid and reliable
in daily clinical practice in AS patients.
Taking into account these information we addressed
the aims of our study in the following points: 1) to test
the construct validity of the SASDAS to define disease
activity in patients with axial SpA and 2) to compare its
internal and external responsiveness with ASDAS CRP/
ESR and the BASDAI, in an observational cohort of
patients with axial SpA.
Methods
Patient characteristics
The investigated cohort included 397 consecutive axial
SpA patients (298 men, 99 women; range 19–78 years
old, mean age 53.4 years old) with disease duration of
5.1 years (SD 11.8). The classification of axial SpA was
based on fulfilment of the ASAS classification criteria
that are defined as follows: the presence of sacroiliitis
by radiography or by magnetic resonance imaging (MRI)
plus at least one SpA feature (“imaging arm”) or the
presence of HLA-B27 plus at least two SpA features
(“clinical arm”) [3,4]. Radiographs were scored for
sacroiliitis according to the modified New York criteria
[15] (defined as grade I: some blurring of the joint mar-
gins – suspicious, grade II - minimal sclerosis with some
erosion, grade III: definite sclerosis on both sides of
joint - severe erosions with widening of joint space with
or without ankylosis, grade IV: complete ankylosis).
The anatomical region of the axial skeleton evaluated
by MRI was chosen by both rheumatologist and radiolo-
gist after consensus, according to the patient’s symptoms
and including always the sacroiliac joints [16-18]. MRI
Salaffi et al. Health and Quality of Life Outcomes 2014, 12:129 Page 3 of 12
http://www.hqlo.com/content/12/1/129of the sacroiliac joints was performed in 31 patients.
MRI of the sacroiliac joints plus the spine was per-
formed in further 9 patients. Patients with peripheral
arthritis were excluded by our study. Peripheral arthritis
was considered in presence of clinical tender and swollen
joints assessed by a rheumatologist. Polyarthritis was de-
fined as five or more inflamed (swollen or tender) joints
as suggested by Helliwell et al. [19]. Further exclusion
criteria were the following: other active concomitant
musculoskeletal diseases (e.g. gout or CPPD, rheumatoid
arthritis), history of cancer or lymphoproliferative dis-
ease, uncontrolled diabetes, unstable ischemic heart dis-
ease, congestive heart failure, active inflammatory bowel
disease, positive serology for hepatitis B, history of active
tuberculosis and concomitant fibromyalgia [20]. All pa-
tients were treated with non-steroidal antiinflammatory
drugs on an on-demand basis and 77 patients (19.4%)
were taking low-dose of corticosteroids (mean 4.6 mg/day
of prednisolone, range 2.5–16 4.6 mg/day).
One-hundred and fifty-six patients (119 women, 37
men; range 19–76 years old, mean age 54.6 years old),
were followed for 6 months. Considering that it was not a
randomised trial, drug therapy was chosen by the man-
aging clinician as considered the most appropriate [21,22].
At baseline, 29 patients were already treated with sulfa-
salazine (SSZ) previously commenced in primary care (25
patients) or in gastroenterology setting (4 patients affected
by inflammatory bowel disease). The dosage of SSZ was
2.0 g/day or up to 3.0 g/day depending on the efficacy and
tolerance. In 21 of 29 SSZ was replaced with anti-TNF
blockers within the third month after the recruitment.
The remaining 8 patients continued treatment with non-
steroidal antinflammatory drugs (NSAIDs) administered
periodically. A total 127 patients were on TNF-blockers
(81.4%), including infliximab (29.9%), etanercept (33.1%)
and adalimumab (37%). Infliximab (5 mg/kg) was given
intravenously at baseline and after two and six weeks
and, by then, every eight weeks. In case of inadequate
response, the frequency of infliximab treatment was
raised to every six weeks. Etanercept was administered
as a subcutaneous injection once (50 mg) or twice
(25 mg) a week. Adalimumab (40 mg) was administered
as a subcutaneous injection on alternate weeks. The
choice of the anti TNF agent was based on the judgment
of the rheumatologist and/or on the specific needs of
the patient. Patients were allowed to receive concomi-
tant medication as usual in daily clinical practice.
All patients were attending the outpatient and
inpatient clinics of the Rheumatology Department of the
Università Politecnica delle Marche (Ancona, Italy) and
they represent a “real life” sample of axial SpA. The
study was approved by the Hospital Clinic ethics
committee. All patients agreed to be enrolled in the
study and signed informed consent.Measures of disease activity
Clinical and laboratory outcome assessments were
performed at baseline and after 24 week and include the
evaluation of BASDAI, ASDAS based on ASDAS-CRP
or ASDAS-ESR and SASDAS indices. The ESR (mm/
hour) and CRP serum levels (mg/dl) were also collected.
The BASDAI contains six items representative of disease
activity in AS [23]. Each item is provided of a 10‐cm
horizontal numerical rating scale (NRS) anchored by
adjectival descriptors ‘none’ and ‘very severe’. Item 6
(morning stiffness, duration) is anchored by a time scale
(0–2 h). The mean of items 5 (morning stiffness, sever-
ity) and 6 is calculated. The total score is converted to a
0–10 scale, with a lower score indicating lower disease
activity. A cutoff level of 4 is used to define the presence
of an active disease [24]. Usually, patients understand
and prefer NRS more than visual analogue scale (VAS)
[25,26].
ASDAS is a composite score of disease activity com-
prising three items from BASDAI (1) back pain (ques-
tion 2), (2) peripheral pain/swelling (question 3) and (3)
duration of morning stiffness (question 6), and patient’s
global assessment and CRP. The development studies re-
sulted in four candidate ASDAS scores, that fulfilling the
clinimetric properties of truth, feasibility and discrimin-
ation. The membership has selected the ASDAS with
CRP as the preferred version and with ESR as the alter-
native version [10,11]. The ASDAS formulas are the
following:
ASDAS −CRP = 0.121 ∗ backpain+ 0.058 ∗ duration of
morning stiffness + 0.110 ∗ patient ' s global assessment +
0.073 ∗ peripheral pain/swelling + 0.579 ∗ Ln(CRP + 1).
ASDAS − ESR = 0.079 ∗ back pain + 0.069 ∗ duration
of morning stiffness + 0.113 ∗ patient's global assessment
+ 0.086 ∗ peripheral pain/swelling + 0.293 ∗ √ (ESR).
CRP is in mg/litre, ESR is in mm/h; the range of other
variables is from 0 to 10; Ln represents the natural
logarithm; √ represents the square root.
The ASDAS has been validated and found to be dis-
criminatory in assessing disease activity in axial SpA and
it has been endorsed by the ASAS and by Outcome
Measures in Rheumatology (OMERACT) [27]. The pub-
lished cut-offs of ASDAS are the following: <1.3 for
inactive disease, <2.1 for moderate disease activity, <3.5
for high disease activity, and ≥3.5 for very high disease
activity. An improvement of ≥ 1.1 units is considered as
a clinical significant improvement and an improvement
of two units is considered as a major response [27,28].
SASDAS was calculated by the simple linear addition of
ASDAS which includes five components: patient global
assessment (NRS 0–10 cm), back pain (BASDAI ques-
tion no. 2), peripheral pain and swelling (BASDAI
Salaffi et al. Health and Quality of Life Outcomes 2014, 12:129 Page 4 of 12
http://www.hqlo.com/content/12/1/129question no. 3), duration of morning stiffness (BASDAI
question no. 6), and ESR in millimeters per hour, divided
by 10. The cut-off values for SASDAS were the follow-
ing: inactive disease from 0 to 7.8, moderate disease
activity from 7.9 to 13.8, high disease activity from 13.9
to 27.6 and very high activity above 27.6 [12].
Functional limitation and health status assessments
Functional limitation and health status assessments were
performed at baseline and include an evaluation of Bath
Ankylosing Spondylitis Functional Index (BASFI) [29]
and EuroQol five-dimensional (EQ-5D) questionnaire
[30]. The BASFI consists of 10 questions designed to
determine the degree of functional limitation in patients
with AS. Each question is answered using an 11-
numbered button NRS format, with a recall period of
the past week. The mean of the 10 scales affords the
BASFI score - a value between 0 and 10, with a lower
score indicating less functional limitation [29]. The
paper formats in the Italian language of the BASFI and
the BASDAI indices, previously validated were employed
in this study [31]. The EQ-5D health state classifier
consists of 5 single-item dimensions - mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression -
with 3 levels of response for no, some, or extreme prob-
lems in each dimension [30]. In addition to the health
state classifier, patients rated their current health on a
20-cm visual analog scale (EQ-5D VAS) ranging from 0
(worst possible health state) to 100 (best possible
health state). Responses to these five dimensions are
converted into one of 243 different EQ-5D health state
descriptions, which range between no problems on all
five dimensions (11111) and severe/extreme problems
on all five dimensions (33333). The Italian population-
based values were used to convert patient responses to
the health state classifier into a single index, which
produces scores from 1 to −0.38 [32].
Statistical analysis
Data related to composite indices and BASDAI showed a
parametric distribution (tested with the Kolmogorov–
Smirnov test) and were presented as means with standard
deviations (SDs). Whereas BASFI and EQ-5D showed a
non-normal distribution (tested with the Kolmogorov–
Smirnov test). Overall agreement (defined as the per-
centage of observed exact agreements) of SASDAS and
different cut-off ASDAS ESR/CRP activity states were
calculated by weigthted Cohen’s kappa coefficients. Evi-
dence for construct validity can only be accumulated by
‘a priori’ hypothesized patterns of associations with
other validated instruments. In this study, the construct
validity of the SASDAS was examined in two ways. First,
we examined construct convergent validity by correlat-
ing the scores of the SASDAS index with ASDAS CRP/ESR, BASDAI, BASFI and EQ-5D. A specific subscale is
expected to converge with the scores of those instruments
targeting the same construct and to deviate from the
scores given by instruments or scales assessing a different
one (divergent validity). To quantify these relationships,
Pearson’s correlation coefficient and Spearman’s rho cor-
relation coefficients were obtained. Correlations > 0.90
were interpreted as very high, 0.70–0.89 as high, 0.50–
0.69 as moderate, 0.26–0.49 as low and ≤ 0.25 as little if
any correlation occurred. Furthermore, we have created
patient groups based on the patients’ activity ranks within
the cohort and used Cohen’s weighted Kappa coefficients
to assess the level of agreement of different activity
categories on individual patients. For this purpose, the
ASDAS cut-off scores were categorised into 4 groups [28].
Similarly, the SASDAS scores were categorised into
4 groups as follows: from 0 to 7.8 (inactive disease), from
7.9 to 13.8 (moderate disease activity), from 13.9 to 27.6
(high disease activity), and above 27.6 (very high activity)
[12]. Responsiveness was evaluated by longitudinal assess-
ment of patients, investigating if the measures were sensi-
tive to change following the intervention. Responsiveness
refers to the ability of an elicitation method to accurately
detect a meaningful change over time when it has oc-
curred. In accordance with Husted et al. [33], we distin-
guished between internal and external responsiveness.
Internal responsiveness refers to the ability of a measure
to change over a pre-established time frame, whereas
external responsiveness describes the relationship between
changes in a measurement and changes in a reference
measure of disease activity. To assess the magnitude of
the internal responsiveness, we have calculated the effect
size (ES) and standardized response mean (SRM) [34].
The ES is defined as the mean change in the score be-
tween baseline and follow-up, which is divided by the SD
of the baseline score. The SRM is defined as the mean
change in the scores between baseline and follow-up
which is divided by the SD of the individual changes in
the scores. Higher values of ES or SRM mean greater
responsiveness of the measure. Values ≤ 0.5, between 0.5
and 0.8, and ≥ 0.8 were considered to represent small,
moderate and large degrees of responsiveness, respect-
ively. Considering that each of these indices is sensitive to
change for the declined group, we supplemented them by
computing the paired samples t-test statistic for the differ-
ence in change scores. Change between baseline and 6-
month follow-up assessments was considered significant
when p < 0.05. External responsiveness was investigated
with receiver operating characteristic (ROC) curve ana-
lysis in categories of respondents, stratified according
to the response on an item on change in overall health
during the past 6-months. We used item two of the SF-36
Health Survey (SF-36) questionnaire (“compared to 6-months
ago, how would you rate your health in general now?
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same, 4 = somewhat worse, 5 = much worse”) to rate the
overall change. This method has the advantage of syn-
thesizing information on the sensitivity and specificity
for detecting improvement by an external criterion [34].
The area under the ROC curve (AUC-ROC) in this
setting can be interpreted as the probability of correctly
identifying the improved patients from non-improved
patients. This area ranges from 0.5 (no accuracy in dis-
tinguishing improved from non-improved) to 1.0 (per-
fect accuracy). According to Swets [35] areas from 0.50
to 0.70 represent poor accuracy, those from 0.70 and
0.90 are useful for some purposes and higher values rep-
resent high accuracy. Since ROC analysis requires exter-
nal criteria to be dichotomous, the categories of “about
the same, somewhat worse” and “much worse” were col-
lapsed to one variable (non-improved patients) for our
analysis. The non-parametric Wilcoxon signed ranks
test is used for calculation and comparison of the areas
under the ROC curves derived from the sample of
patients, as suggested by Hanley and McNeil [36]. All
data were entered into a Microsoft Access database
which was developed for the management of the cross-
sectional study. All the statistical analyses were per-
formed using the SPSS version 15.0 (SPSS Inc, Chicago,
USA) and the MedCalc® version 11.0 (MedCalc Software,
Mariakerke, Belgium).
Results
Table 1, shows the demographic, laboratory and clinical
data of the cohort of patients.
Score distributions of the disease activity indices
Additional file 1 summarizes the descriptive statistics for
SASDAS and ASDAS ESR/CRP scores, BASDAI, BASFI
and EQ-5D. Figure 1 presents estimates of central ten-
dency and distribution of score for SASDAS (A), ASDAS
ESR/CRP (B-C), BASDAI (D), BASFI (E) and EQ-5D (F)
in all patient at baseline (N = 357 patient). The bar on
the left of each graph represents the number of subjects
with a score of 0 (floor effect); the bar on the right rep-
resents the number of subjects with a maximum possible
score (ceiling effect). All activity indices were normally
distributed whereas BASFI and EQ-5D showed a non-
normal distribution. The mean (SD) were as follows:
SASDAS 20.18 (7.33), ASDAS-ESR 2.48 (0.65), ASDAS-
CRP 2.56 (0.77), BASDAI 4.10 (1.48), BASFI 4.47 (1.99)
and EQ-5D 0.70 (0.13).
Construct validity of the SASDAS in cross-sectional study
Concurrent validity
There was a very high degree of correlation between the
composite indices. The indices were correlated signifi-
cantly with all other comparator scores (p < 0.0001). Thehighest correlations were seen between SASDAS and
ASDAS-ESR (r = 0.835) and between SASDAS and BAS-
DAI score (r = −0.886). Strong correlations were also
found between SASDAS and ASDAS-CRP (r = 0.805),
SASDAS and BASFI (rho = 0.588) and SASDAS and EQ-
5D (rho = −0.579) (Figure 2). The SASDAS showed no
significant relationship with age and disease duration.
Categorizing patients according to the proposed SAS-
DAS disease activity scoring system revealed 20 patients
(5.0%) with inactive disease, 84 patients (21.2%) with
moderate disease activity, 246 patients (62.0%) with high
disease activity and 47 patients (11.8%) with very high
disease activity. According to the ASDAS-ESR, 24 pa-
tients (6.0%) had inactive disease, 64 patients (16.1%)
moderate disease activity, 241 patients (60.7%) high dis-
ease activity and 68 patients (17.1%) very high disease
activity. The cross-classification showed a significant
agreement (weighted Kappa 0.704 with standard error of
0.038) (Table 2). The categorization of cut-off of SAS-
DAS versus those of the ASDAS-CRP index have basic-
ally confirmed the agreement of the previous one
(weighted Kappa 0.661 with standard error of 0.039)
(Table 2).
a) Internal responsiveness
Effect size and standardized response mean statistics
All composite indices were responsive in detecting dis-
ease activity in the cohort of patients, with ES and SRM
values higher observed from the BASDAI (Table 3). The
most efficient composite measure in detecting change
was the ASDAS-CRP (ES 1.95 and SRM 0.97). The least
responsive in detecting change was the BASDAI (ES =
0.93 and SRM = 0.52). The responsiveness of SASDAS
was slightly higher to ASDAS-ESR with an ES of 1.62
and 1.33, respectively and an SRM of 0.88 and 0.71. In-
spection of ES reveals that this index gives the highest
values.
b) External responsiveness
Receiver operating characteristic (ROC) curve analysis
Figure 3 shows the ROC plots of changing scores of the
three traditional composite disease activity indices and
BASDAI, by using the item two on the SF-36 question-
naire to rate the overall change as an external criterion.
For SASDAS, ASDAS-ESR, and ASDAS-CRP the AUC
were 0.870 ± 0.031 (95% C.I. from 0.808 to 0.932), 0.794 ±
0.037 (95% C.I. from 0.721 to 0.867) and 0.882 ± 0.028
(95% C.I. from 0.826 to 0.937), respectively. Concerning
the ROC plots of the change score of questionnaire, the
AUC for BASDAI AUC was 0.787 ± 0.041 (95% C.I. from
0.704 to 0.868) (Additional file 2). The difference be-
tween changing scores of BASDAI and both SASDAS
and ASDAS-CRP were significant (differences between
areas = 0.085 ± 0.038 with 95% CI 0.009–0.161; p = 0.026
Table 1 Demographic, laboratory and clinical characteristics of study population
Patients characteristics Mean SD Median 25 - 75 P
Age (years) 53.40 11.78 54.00 45.00 - 62.00
Disease duration (years) 5.13 4.95 4.00 2.00 - 7.00
ASDAS-ESR 2.48 0.65 2.49 2.06 - 2.93
ASDAS-CPR 2.56 0.77 2.53 2.04 - 3.13
SASDAS (0–10) 20.18 7.33 20.10 14.30 - 25.82
BASDAI (0–10) 4.10 1.48 4.00 3.15 - 5.12
• BASDAI item 1: fatigue/tiredness 6.00 2.34 6.00 4.00 - 8.00
• BASDAI item 2: neck back or hip pain 5.04 2.16 5.00 3.75 - 7.00
• BASDAI item 3: pain and swelling in other joints 4.88 2.65 5.00 3.00 - 7.00
• BASDAI item 4: discomfort from areas tender to touch 1.98 1.38 2.00 1.00 - 2.25
• BASDAI item 5: level of morning stiffness 3.73 1.83 3.50 2.50 - 5.00
• BASDAI item 6: duration of morning stiffness 3.61 2.24 3.00 2.00 - 5.00
BASFI (0–10) 4.47 1.99 4.44 3.20 - 5.55
EQ-5D score (0–1) 0.70 0.13 0.68 0.61 - 0.78
Patient’s global status (0–10) 5.05 2.38 5.00 4.00 - 7.00
CRP level, mg/l 9.19 9.28 6.10 3.30 - 11.44
ESR, mm/hour 17.4 10.51 16.50 8.40 - 20.80
Abbreviations: (ASDAS) Ankylosing Spondylitis Disease Activity Score, (SADSAS) Simplified Ankylosing Spondylitis Disease Activity Score, (BASDAI) Bath Ankylosing
Spondylitis Disease Activity Index, (BASFI) Bath Ankylosing Spondylitis Functional Index, (EQ-5D) EuroQol five-dimensional questionnaire, (ESR) Erythrocyte
Sedimentation Rarate, (CRP) C-Reactive Protein.
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Comparison of score changes by longitudinal analysis
To further investigate the external responsiveness
changing scores of composite disease activity indices were
compared by calculating correlation coefficients. TheFigure 1 Histograms demonstrating central-tendency estimation and
indices (B-C), BASDAI (D), BASFI (E) and EQ-5D (F). The bar on the left o
of 0 (floor effect). The bar on the right represents the number of subjects wchanging scores of all combinations were highly correlated
(p < 0.0001) (Figure 4). In particular, there was a strong
correlations between mean change of the ASDAS-ESR
score with changes of the SASDAS (r = 0.784, p < 0.0001)
(A) and between mean change of the ASDAS-CRP and
SASDAS score (r = 0.774, p < 0.0001) (B). Similarly, we
have found a significant, but lower correlation, betweendistributions of SASDAS (A) and ASDAS ESR/CRP composite
f each group represents the number of subjects with a score
ith a maximum possible score (ceiling effect).
Figure 2 Scatter plots of the composite disease activity indices at baseline. All analyses indicate a highly significant degree (p < 0.0001) of
correlation among the composite indices: (A) SASDAS versus ASDAS-ESR, (B) SASDAS versus ASDAS-CRP, (C) SASDAS versus BASDAI, (D) SASDAS
versus BASFI, (E) SASDAS versus EQ-5D.
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the BASDAI (r = 0.660, p < 0.0001) (C).
Discussion
Several recent studies have been performed to identify
and measure the outcomes of treatment of axial SpA in
both research and clinical practice. The development of
valid, reproducible and objective tool for the evaluation of
disease activity in axial SpA is difficult, although valuable
instruments have been recommended by several re-
searchers [37]. Among the proposed composite indices,
BASDAI has acceptable properties as a measure of disease
activity in axial SpA. Nevertheless, there are few issues
with regard the items content and appropriateness of
response formats of BASDAI [38]. Further, it has beenTable 2 Overall agreement (defined as the percentage of obs
for different activity states in the axial SpA patient cohort at
Cut-off SASDAS
Very high Hi




Total (%) 47 (11.8%) 24




Total (%) 68 (17.1%) 24shown that the BASDAI is an ambiguous measure of dis-
ease activity in patients with peripheral or axial disease ac-
tivity and that reflects only patient’s perspectives and not
necessarily captures the entire spectrum of disease activity
[39]. For that reason ASAS group has tried to go a step
further in the evaluation of disease activity in AS by devel-
oping the ASAS-endorsed disease activity score (termed
ASDAS) [10]. The ASDAS is an index that tries to reflect
several aspects of disease activity and correlates well with
both physician’s and patient’s perception of disease activ-
ity, with respect to BASDAI. Furthermore, ASDAS has
been shown to well correlate with biomarkers of cartilage
[e.g. matrix metalloproteinase 3 (MMP-3) and osteocalcin]
and bone turnover (e.g. C-terminal crosslinking telopep-
tide of type II collagen) [40]. This indicates that ASDAServed exact agreements) of SASDAS and ASDAS-ESR/CRP
baseline (397 patients)
ght Moderate Inactive Total
0 0 68 (17.1%)
2 26 0 241 (60.7%)
54 0 64 (16.1%)
4 20 24 (6.0%)
6 (62.0%) 84 (21.2%) 20 (5.0%) 397
0 0 50 (12.6%)
8 14 0 246 (62.0%)
50 5 82 (20.7%)
0 19 19 (4.8%)
1 (60.7%) 64 (16.6%) 24 (6.0%) 397
Table 3 Responsiveness statistics for SASDAS, ASDAS-ESR, ASDAS-CRP and BASDAI for patients with axial-SpA at














SASDAS 22.81 (5.19) 14.78 (7.07) 8.15 (9.23) −10.98 (p < 0.0001) 1.62 0.88
ASDAS-ESR 2.60 (0.48) 2.01 (0.62) 0.60 (0.85) −8.79 (p < 0.0001) 1.33 0.71
ASDAS-CRP 2.84 (0.52) 1.90 (0.73) 0.95 (0.97) −12.16 (p < 0.0001) 1.95 0.97
BASDAI 4.45 (1.13) 3.69 (1.42) 0.71 (1.08) −6.129 (p < 0.0001) 0.92 0.52
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SpA with comparison to BASDAI.
Even the final decision to define the most appropriate
set of domains of ASDAS has not yet been taken, ASDAS-
CRP is the one widely recommended [11]. ASDAS was
found to be applicable also in subgroups without elevated
CRP and/or peripheral swelling joints [41].
Despite the excellent psychometric properties of
ASDAS for the evaluation of disease activity in axial
SpA, this index is not easy to use in the everyday clinical
practice. This relevant aspect has recently led to a major
revision of ASDAS, in order to simplify the index [12].Figure 3 ROC curves illustrating the relationship between
sensitivity and complement of specificity (100 specificity) in
axial SpA for the composite disease activity indices (ASDAS-ESR,
ASDAS-CRP and SASDAS) and BASDAI, by using changes of
global disease activity as external indicator. The area under the
ROC curve (AUC) can be interpreted as the probability of correctly
identifying patients improved form those not-improved. A line that
runs diagonally across the figure from lower left upper right will have
an area of 0.5 which represent an instrument not able to discriminate
different status of disease activity.Undoubtedly, the SASDAS index improves the evalu-
ation of disease activity in daily practice and real-life
conditions and, moreover, complies the recommenda-
tions of the OMERACT group [42].
In our study we have investigated the construct valid-
ity of the SASDAS in evaluating the disease activity and
we have compared the internal and external responsive-
ness of SADSAS and ASDAS ESR/CRP and traditional
BASDAI in a cohort of patients with axial SpA. Com-
pared with conventional clinical measures of disease
activity, functional and general health status, SASDAS
have demonstrated adequate construct validity and was
equally or more responsive to changes in disease activity
than conventional composite measures.
Similarly to the original study [12], we have found a very
high degree of correlation between these composite indi-
ces. The highest correlations were seen between SASDAS
and ASDAS-ESR and between SASDAS and BASDAI
score. Strong correlations were also found between SAS-
DAS and ASDAS-CRP, SASDAS and BASFI and SASDAS
and EQ-5D. Further, the categorization of cut-off of
SASDAS versus those of both the ASDAS CRP/ESR have
confirmed a significant high overall agreement.
It was recently shown that ASDAS performs better
than BASDAI in evaluating disease activity in patients
with AS. In particular, Lukas et al. [10] and van der
Heijde et al. [11] have documented a better discrimin-
atory capacity of ASDAS sets compared to BASDAI.
Vastesaeger et al. [43], in concordance with validation of
the ASDAS [11], have demonstrated that ASDAS dis-
criminate better than BASDAI in patients with elevated
CRP and was equal to BASDAI in patients with normal
CRP. The ASDAS is also a highly effective measure in
assessing disease activity and a great discriminatory
measurement to assess the efficacy of TNF-a inhibitor in
AS and undifferentiated SpA [44]. However, three other
studies that have assessed the validity of BASDAI and
ASDAS sets in patients with axial PsA showed conflict-
ing results. Taylor and Harrison [39] have concluded
that BASDAI correlated well with patient perception of
disease activity but, was unable to discriminate well
between high and low disease activity. Fernández-Sueiro
Figure 4 Scatter plot of patient data showing the change in SASDAS compared with the change score of ASDAS-ESR (A), ASDAS-CRP
(B) and BASDAI (C) at 6 months of follow-up. Changes of SASDAS were all significantly (p < 0.0001), related to changes of ASDAS-ESR
ASDAS-CRP and BASDAI, in response to treatment (r = 0.784; r = 0.774 and r = 0.807).
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in differentiating between patients with axial-PsA and
those without axial involvement. Eder et al. [46] have
demonstrated that in patients with axial-PsA, ASDAS
and BASDAI scores show similar discriminative ability
(from moderate to good) and correlation with different
constructs of disease activity. ASDAS was not superior
to BASDAI in its ability to discriminate between high
and low disease activity states in axial-PsA. A confound-
ing factor in these studies that may account for the dis-
crepancy between the results obtained in the axial-PsA
could be due to the presence of peripheral arthritis. In
fact the peripheral arthritis, in these cases, may have an
impact on disease activity level when it is assessed using
BASDAI. This may be an advantage of ASDAS with
respect to BASDAI, which is affected by peripheral
involvement to various degrees, even in subjects with
predominantly axial involvement [47,48].
Up-to-date, in clinical practice the decision to start or
continue DMARDs or TNF-a blocking therapy in
patients with axial SpA is mainly based on BASDAI
response, which is solely based on the opinion of the
patient. Our results showed that the simplified version
of the ASDAS (SASDAS) was sensitive to improvement
in patients with axial SpA receiving TNF-inhibitors, with
an ES of 1.62 and a SRM of 0.88, and was more respon-
sive than BASDAI (ES 0.93, SRM 0.52). The most effi-
cient composite measure in detecting changes of disease
activity was the ASDAS-CRP (ES 1.95; SRM 0.97),
whereas the ASDAS-ESR showed an intermediate be-
haviour (ES 1.33; SRM 0.71).
Our results are consistent with the literature data and
further support the good psychometric properties of the
ASDAS. In particular, in a 46 weeks prospective, longitu-
dinal multi-center study, Pedersen et al. [49] have investi-
gated the construct validity and responsiveness of the
ASDAS-CRP in patients with SpA treated with anti-TNF
drugs. The authors demonstrated that ASDAS had higher
responsiveness compared to BASDAI and CRP and
thresholds for BASDAI at 20 mm or 50% improvementcorresponding to an ASDAS of 1.38 and 1.95, respectively.
ASDAS-CRP has demonstrated the highest responsiveness
with an effect size of 2.04 and a standardized response
mean of 1.45, whereas BASDAI (1.86; 1.36) and CRP
(0.63; 0.70) were less responsive. Similarly, in a post hoc
analysis of the randomized controller ASCEND trial, van
der Heijde et al. found that ASDAS is a validated and
highly discriminatory tool for the detection of significant
differences between treatments for AS as well as for
detecting a significant improvement from baseline with
etanercept and SSZ [50].
Although comparable responses in the ASAS 20,
ASAS 40 and ASAS 5/6 and the BASDAI 50 have been
achieved by adalimumab, etanercept and infliximab
[51-53], low to moderate levels of responsiveness were
reported for the BASDAI in placebo-controlled trials
and longitudinal evaluation of active drugs [54,55], in
longitudinal evaluation of in-patient rehabilitation [56]
or in combined spa and exercise therapy [57-61]. Mean
score change for the BASDAI did not exceed 1.9 and 1.3
respectively following all physical therapy interventions
within a 2 to 40-week follow-up period.
Our study was designed to test the performance of
the SASDAS versus ASDAS ESR/CRP and BASDAI in
the clinical routine setting, so, we aware that it presents
some limitations. First, we have not correlated the
composite indices with structural damage and to en-
sure criterion validity of the composite indices. How-
ever, this is the subject of an ongoing study. Second,
our study was performed in a single centre within a
relatively small catchment area. Third, our work was
concentrated only to the simplified version of ASDAS-
ESR. We aware tha it would be of great interest to test
also the ASDAS-CRP which is currently preferred for
the assessment of axial SpA. Our research agenda is
currently addressed to this topic in order to improve
the scientific interest. Further, it remains to be seen in
future long-term analyses whether the presented SAS-
DAS cut-offs for different stages of disease activity will
show similar results.
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http://www.hqlo.com/content/12/1/129In conclusion, in patients with axial SpA the ASDAS
scoring system and SASDAS scores show similar good
discriminative ability and correlation with different con-
structs of disease activity and health status. The SAS-
DAS score did not improve its discriminative ability and
responsiveness compared with ASDAS scoring systems.
Therefore, since SASDAS is easier to calculate, it may be
more practical for clinical use in patients with axial SpA.
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